Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TADA: APO-Dabigatran PK with Rabeprazole
NCT04157881Phase 4Completed
- Sponsor
- Population Health Research Institute
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (2 arms), sponsored by Population Health Research Institute. Primary endpoints: Peak Plasma Concentration at 24 hours and Area Under the Curve at 24 hours. Started Jan 2020; status: completed.
02
Drugs
dabigatran
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04157881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157881.